Molecular responses and chromosomal aberrations in patients with polycythemia vera treated with peg-proline-interferon alpha-2b

Fifty-one polycythemia vera (PV) patients were enrolled in the phase I/II clinical study PEGINVERA to receive a new formulation of pegylated interferon alpha (peg-proline-IFNα-2b, AOP2014/P1101). Peg-proline-IFNα-2b treatment led to high response rates on both hematologic and molecular levels. Hemat...

Descripción completa

Detalles Bibliográficos
Autores principales: Them, Nicole CC, Bagienski, Klaudia, Berg, Tiina, Gisslinger, Bettina, Schalling, Martin, Chen, Doris, Buxhofer-Ausch, Veronika, Thaler, Josef, Schloegl, Ernst, Gastl, Guenther A, Wolf, Dominik, Strecker, Karin, Egle, Alexander, Melchardt, Thomas, Burgstaller, Sonja, Willenbacher, Ella, Zagrijtschuk, Oleh, Klade, Christoph, Greil, Richard, Gisslinger, Heinz, Kralovics, Robert
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Ltd 2015
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4657499/
https://www.ncbi.nlm.nih.gov/pubmed/25545244
http://dx.doi.org/10.1002/ajh.23928

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4657499/
https://www.ncbi.nlm.nih.gov/pubmed/25545244
http://dx.doi.org/10.1002/ajh.23928

Ejemplares similares